Source comparison
Published Dosing Protocols — What Research Uses vs What's Marketed
The gap between research dosing and commercial peptide marketing is significant. Published studies in humans have used subcutaneous injections ranging from 5mg to 15mg, administered either daily or every other day for durations of 7–28 days. The USC metabolic
This comparison does not assign a generated winner or score.
- The gap between research dosing and commercial peptide marketing is significant. Published studies in humans have used subcutaneous injections ranging from 5mg to 15mg, administered either daily or every other day for durations of 7–28 days. The USC metabolic study used 5mg daily for 14 days in insulin-resistant subjects. The Japanese aging research used 10mg three times weekly for four weeks.
- Animal studies typically dose MOTS-c at 5mg/kg body weight intraperitoneally (injected into the abdominal cavity), which translates to approximately 350–400mg for a 70kg human if you scale by body weight. But interspecies dose conversion isn't linear. Most researchers suggest human-equivalent doses are likely in the 5–20mg range based on receptor saturation modeling, though no large-scale pharmacokinetic study has confirmed optimal dosing.
- What you won't find in peer-reviewed literature: dosing recommendations above 20mg, oral formulations with proven bioavailability, or "loading phases" followed by maintenance doses. The research-grade peptides used in published trials are lyophilised (freeze-dried) powders reconstituted with bacteriostatic water immediately before injection. Stability data shows reconstituted MOTS-c degrades at room temperature within 48–72 hours, which is why studies use fresh preparations.
- Our experience reviewing peptide research protocols shows that when a commercial product claims "research-backed dosing," it's worth checking whether that backing comes from peer-reviewed human trials or extrapolated animal data. For MOTS-c specifically, the human evidence base is limited to fewer than five published studies as of 2026. Enough to demonstrate biological activity, not enough to establish clinical dosing standards.